TrialLancet (London, England)2012

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

José Baselga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.